- Home
- AGEN vs LICN Comparison
AGEN vs LICN Comparison
Compare AGEN & LICN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- LICN
- Stock Information
- Founded
- AGEN 1994
- LICN 2004
- Country
- AGEN United States
- LICN China
- Employees
- AGEN N/A
- LICN N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- LICN
- Sector
- AGEN Health Care
- LICN
- Exchange
- AGEN Nasdaq
- LICN Nasdaq
- Market Cap
- AGEN 87.7M
- LICN 3.0M
- IPO Year
- AGEN 2000
- LICN 2023
- Fundamental
- Price
- AGEN $5.51
- LICN $4.18
- Analyst Decision
- AGEN Buy
- LICN
- Analyst Count
- AGEN 4
- LICN 0
- Target Price
- AGEN $13.00
- LICN N/A
- AVG Volume (30 Days)
- AGEN 1.3M
- LICN 70.7K
- Earning Date
- AGEN 08-07-2025
- LICN 01-01-0001
- Dividend Yield
- AGEN N/A
- LICN N/A
- EPS Growth
- AGEN N/A
- LICN N/A
- EPS
- AGEN N/A
- LICN N/A
- Revenue
- AGEN $99,524,000.00
- LICN $41,477,000.00
- Revenue This Year
- AGEN $12.69
- LICN N/A
- Revenue Next Year
- AGEN N/A
- LICN N/A
- P/E Ratio
- AGEN N/A
- LICN N/A
- Revenue Growth
- AGEN N/A
- LICN 4.32
- 52 Week Low
- AGEN $1.38
- LICN $2.60
- 52 Week High
- AGEN $18.74
- LICN $488.00
- Technical
- Relative Strength Index (RSI)
- AGEN 62.45
- LICN 46.64
- Support Level
- AGEN $4.34
- LICN $4.00
- Resistance Level
- AGEN $5.22
- LICN $4.38
- Average True Range (ATR)
- AGEN 0.43
- LICN 0.26
- MACD
- AGEN -0.05
- LICN 0.01
- Stochastic Oscillator
- AGEN 92.86
- LICN 60.00
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About LICN Lichen China Limited
Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and sales of financial and taxation training software.